Articles published by TRex Bio, Inc.

TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics

Today 7:00 EST

From TRex Bio, Inc.

Via Business Wire

TRexBio to Participate in Upcoming Investor Conferences in September

September 03, 2025

From TRex Bio, Inc.

Via Business Wire

TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases

June 03, 2025

From TRex Bio, Inc.

Via Business Wire

TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer

April 08, 2025

From TRex Bio, Inc.

Via Business Wire

TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development

November 13, 2024

From TRex Bio, Inc.

Via Business Wire

TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases

June 26, 2024

From TRex Bio, Inc.

Via Business Wire

TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration

January 03, 2024

From TRex Bio, Inc.

Via Business Wire

TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Diseases

November 14, 2023

From TRex Bio, Inc.

Via Business Wire

TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases

January 09, 2023

From TRex Bio, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.